Comparison of labetalol and propranolol in hypertension
- PMID: 6988003
- PMCID: PMC1429887
- DOI: 10.1111/j.1365-2125.1980.tb04832.x
Comparison of labetalol and propranolol in hypertension
Abstract
1 Labetalol has been compared with propranolol in a double-blind, double-dummy study of 24 patients with mild or moderate essential hypertension. 2 Two patients were unable to tolerate propranolol and five labetalol, because of symptom side effects; this difference was not significant (P greater than 0.1). 3 On a self-administered questionnaire, labetalol was associated with a greater number of side effects per patient than propranolol, but no individual side effect was significantly more common with either drug. 4 There was no difference in the number of spontaneously reported side effects between the two drugs. 5 Both drugs impaired pulmonary function, but propranolol caused a greater reduction than labetalol after 8 weeks of treatment. 6 We conclude that labetalol and propranolol are similarly effective and acceptable to the patient.
Similar articles
-
A controlled trial of labetalol (Trandate), propranolol and placebo in the management of mild to moderate hypertension.Br J Clin Pharmacol. 1979 Jan;7(1):63-8. doi: 10.1111/j.1365-2125.1979.tb00898.x. Br J Clin Pharmacol. 1979. PMID: 367410 Free PMC article. Clinical Trial.
-
Controlled comparison of labetalol and propranolol in the management of severe hypertension.Br J Clin Pharmacol. 1976 Aug;3(4 Suppl 3):777-82. Br J Clin Pharmacol. 1976. PMID: 791331 Clinical Trial.
-
A double-blind crossover clinical trial of labetalol and propranolol in patients of essential hypertension.Int J Clin Pharmacol Ther Toxicol. 1985 Feb;23(2):101-4. Int J Clin Pharmacol Ther Toxicol. 1985. PMID: 3886563 Clinical Trial.
-
Combined alpha- and beta-receptor inhibition in the treatment of hypertension.Drugs. 1984;28 Suppl 2:51-68. doi: 10.2165/00003495-198400282-00005. Drugs. 1984. PMID: 6151891 Review.
-
Cost effectiveness of labetalol and propranolol in the treatment of hypertension among blacks.J Natl Med Assoc. 1987 Oct;79(10):1049-55. J Natl Med Assoc. 1987. PMID: 3119865 Free PMC article. Review.
Cited by
-
Eliciting adverse effects data from participants in clinical trials.Cochrane Database Syst Rev. 2018 Jan 16;1(1):MR000039. doi: 10.1002/14651858.MR000039.pub2. Cochrane Database Syst Rev. 2018. PMID: 29372930 Free PMC article.
-
Labetalol. A reappraisal of its pharmacology, pharmacokinetics and therapeutic use in hypertension and ischaemic heart disease.Drugs. 1989 May;37(5):583-627. doi: 10.2165/00003495-198937050-00002. Drugs. 1989. PMID: 2663413 Review.
-
Properties of labetalol, a combined alpha- and beta-blocking agent, relevant to the treatment of myocardial ischemia.Cardiovasc Drugs Ther. 1988 Sep;2(3):343-53. doi: 10.1007/BF00054642. Cardiovasc Drugs Ther. 1988. PMID: 2908732 Review.
-
Propranolol vs metoprolol vs labetalol: a comparative study in essential hypertension.Eur J Clin Pharmacol. 1984;26(1):1-6. doi: 10.1007/BF00546699. Eur J Clin Pharmacol. 1984. PMID: 6143666 Clinical Trial.
-
Cold sensitivity in essential hypertension: the effect of beta- and combined alpha- and beta-blockade.Eur J Clin Pharmacol. 1985;29(1):33-6. doi: 10.1007/BF00547365. Eur J Clin Pharmacol. 1985. PMID: 2865156 Clinical Trial.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical